The use of dendritic cell vaccinations in melanoma: where are we now?
作者信息
Halilovic Altuna, Bol Kalijn F
机构信息
Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Department of Pathology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
出版信息
Melanoma Manag. 2016 Dec;3(4):247-250. doi: 10.2217/mmt-2016-0027. Epub 2016 Nov 29.
Abstract
摘要
相似文献
1
The use of dendritic cell vaccinations in melanoma: where are we now?
Melanoma Manag. 2016 Dec;3(4):247-250. doi: 10.2217/mmt-2016-0027. Epub 2016 Nov 29.
2
Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.
Clin Cancer Res. 2010 Oct 15;16(20):5067-78. doi: 10.1158/1078-0432.CCR-10-1757. Epub 2010 Aug 24.
3
Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial).
BMJ Open. 2018 Aug 5;8(8):e021701. doi: 10.1136/bmjopen-2018-021701.
4
Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T).
Future Oncol. 2016 Mar;12(6):751-62. doi: 10.2217/fon.16.13. Epub 2016 Feb 3.
5
Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
Clin Cancer Res. 2011 Sep 1;17(17):5725-35. doi: 10.1158/1078-0432.CCR-11-1261. Epub 2011 Jul 19.
6
[Phase II clinical trial of autologous dendritic cell vaccine with immunologic adjuvant in cutaneous melanoma patients].
Vopr Onkol. 2012;58(2):212-21.
7
Dendritic cell immunotherapy for stage IV melanoma.
Melanoma Res. 2007 Oct;17(5):316-22. doi: 10.1097/CMR.0b013e3282c3a73b.
8
Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2.
Melanoma Res. 2003 Oct;13(5):521-30. doi: 10.1097/00008390-200310000-00011.
9
Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients.
Am J Ophthalmol. 2014 Nov;158(5):939-47. doi: 10.1016/j.ajo.2014.07.014. Epub 2014 Jul 17.
10
Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
J Immunother. 2006 Sep-Oct;29(5):545-57. doi: 10.1097/01.cji.0000211309.90621.8b.
引用本文的文献
1
Melanoma vaccines and viral-based immunotherapies: a special focus issue from .
Melanoma Manag. 2016 Dec;3(4):245-246. doi: 10.2217/mmt-2016-0030. Epub 2016 Nov 30.
2
Naturally produced type I IFNs enhance human myeloid dendritic cell maturation and IL-12p70 production and mediate elevated effector functions in innate and adaptive immune cells.
Cancer Immunol Immunother. 2018 Sep;67(9):1425-1436. doi: 10.1007/s00262-018-2204-2. Epub 2018 Jul 13.
本文引用的文献
1
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
Nature. 2016 Jun 16;534(7607):396-401. doi: 10.1038/nature18300. Epub 2016 Jun 1.
2
Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients.
J Immunother. 2016 Jul-Aug;39(6):241-8. doi: 10.1097/CJI.0000000000000127.
3
T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines.
Cancer Res. 2016 Jun 15;76(12):3496-506. doi: 10.1158/0008-5472.CAN-15-3211. Epub 2016 Apr 11.
4
Dendritic Cell-Based Immunotherapy: State of the Art and Beyond.
Clin Cancer Res. 2016 Apr 15;22(8):1897-906. doi: 10.1158/1078-0432.CCR-15-1399.
5
Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.
Oncoimmunology. 2015 Jun 5;5(1):e1057673. doi: 10.1080/2162402X.2015.1057673. eCollection 2016.
6
Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.
J Clin Oncol. 2016 Apr 20;34(12):1330-8. doi: 10.1200/JCO.2015.63.4121. Epub 2016 Feb 29.
7
Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.
Clin Cancer Res. 2016 May 1;22(9):2155-66. doi: 10.1158/1078-0432.CCR-15-2205. Epub 2015 Dec 28.
8
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.
Cell. 2015 Apr 9;161(2):205-14. doi: 10.1016/j.cell.2015.03.030.
9
Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.
Science. 2015 May 15;348(6236):803-8. doi: 10.1126/science.aaa3828. Epub 2015 Apr 2.
10
Clinical use of dendritic cells for cancer therapy.
Lancet Oncol. 2014 Jun;15(7):e257-67. doi: 10.1016/S1470-2045(13)70585-0.
Zotero 插件